Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Schedule Of Components Of Loss Before Income Tax

The components of (loss) income before income taxes for the years ended twelve months ended December 31, are as follows:


(Loss) Income Before Income Taxes:	2020		2019		2018

Ireland	$	(27,205)	$	(50,134)	$	(42,604)
U.S.	22,335		10,401		(70,340)
France	(212)		1,151		(253)
Total loss before income taxes	$	(5,082)	$	(38,582)	$	(113,197)

Schedule Of Income Tax (Benefit) Provision

The income tax (benefit) provision consists of the following for the years ended December 31:


Income Tax (Benefit) Provision:	2020		2019		2018

Current:
U.S. - Federal	$	(12,810)	$	—	$	—
U.S. - State	20		97		330

Total current	(12,790)		97		330

Deferred:
Ireland	—		(1,256)		—
U.S. - Federal	680		(4,093)		(19,503)
U.S. - State	—		(104)		1,280

Total deferred	680		(5,453)		(18,223)

Income tax benefit	$	(12,110)	$	(5,356)	$	(17,893)

Schedule of Effective Income Tax Rate Reconciliation

The reconciliation between income taxes at the statutory rate and the Company’s benefit for income taxes is as follows for the years ended December 31:


Reconciliation to Effective Income Tax Rate:	2020			2019			2018

Statutory tax rate	12.5		%	12.5		%	12.5		%
Differences in international tax rates	(34.5)		%	3.2		%	8.0		%
Nondeductible changes in fair value of contingent consideration	(19.4)		%	(0.3)		%	4.0		%
Intercompany asset transfer	—		%	21.2		%	—		%
Change in valuation allowances	(83.3)		%	(19.1)		%	(5.3)		%
Nondeductible stock-based compensation	(20.9)		%	(2.7)		%	(1.3)		%
Hospital Products sale	183.5		%	—		%	—		%
Unrealized tax benefits	5.4		%	0.7		%	(1.3)		%
State and local taxes (net of federal)	(0.4)		%	—		%	(0.3)		%
Change in U.S. tax law	179.5		%	—		%	(0.2)		%
Nondeductible interest expense	(34.0)		%	(2.5)		%	(1.1)		%
Orphan drug and R&D tax credit	55.0		%	—		%	—		%
Other	(5.1)		%	0.9		%	0.7		%
Effective income tax rate	238.3		%	13.9		%	15.7		%

Income tax benefit - at statutory tax rate	$	(636)		$	(4,823)		$	(14,149)
Differences in international tax rates	1,755			(1,218)			(9,039)
Nondeductible changes in fair value of contingent consideration	988			121			(4,559)
Intercompany asset transfer	—			(8,190)			—
Change in valuation allowances	4,231			7,379			5,998
Nondeductible stock-based compensation	1,060			1,039			1,499
Hospital Products sale	(9,328)			—			—
Unrecognized tax benefits	(274)			(261)			1,440
State and local taxes (net of federal)	20			(7)			299
Change in U.S. tax law	(9,124)			—			274
Nondeductible interest expense	1,728			982			1,269
Orphan drug and R&D tax credit	(2,793)			—			—
Other	263			(378)			(925)
Income tax benefit - at effective income tax rate	$	(12,110)		$	(5,356)		$	(17,893)

Summary of Unrecognized Tax Benefits

The following table summarizes the activity related to the Company’s unrecognized tax benefits for the twelve months ended

December 31:


Unrecognized Tax Benefit Activity	2020		2019		2018

Balance at January 1:	$	6,465	$	5,315	$	3,954
Additions based on tax positions related to the current year	—		—		1,087
Increases for tax positions of prior years	—		2,416		274
Statute of limitations expiration	—		(1,266)		—
Settlements	(3,322)		—		—
Balance at December 31:	$	3,143	$	6,465	$	5,315

Schedule of Deferred Tax Assets and Liabilities

The net deferred tax assets (liabilities) at December 31, 2020 and 2019 resulted from the following temporary differences:


Net Deferred Tax Assets and Liabilities:	2020		2019

Deferred tax assets:
Net operating loss carryforwards	$	31,302	$	30,275
Amortization	3,701		11,602
Stock based compensation	2,626		3,577
Accounts receivable	—		53
Fair value contingent consideration	—		264
Orphan drug and R&D tax credit	2,793		—
Other	423		901
Gross deferred tax assets	40,845		46,672

Deferred tax liabilities:
Amortization	—		(172)
Prepaid expenses	(75)		(35)
Other	(890)		—
Gross deferred tax liabilities	(965)		(207)

Less: valuation allowances	(21,624)		(17,038)

Net deferred tax assets	$	18,256	$	29,427